Anti-Mouse CD49d – Purified in vivo PLATINUM™ Functional Grade

AKR/Cum mouse Spontaneous T lymphoma line TK1

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Functional grade preclinical antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2-8°C Wet Ice

R1-2 activity is directed against mouse CD49d.

Integrins are a large family of heterodimeric transmembrane molecules that mediate adhesion, migration, cell survival, and cell differentiation. CD49d is a single-pass type I membrane glycoprotein also known as integrin alpha-4 (Uniprot Accession P13612). CD49d is the α4 subunit of integrin heterodimers alpha-4/beta-1 (VLA-4; CD49d/CD29; α4β1 integrin) and alph-4/beta-7 (LPAM-1)¹. These integrins act as receptors for fibronectin and VCAM1 (CD106). Integrin alpha-4/beta-7 is also a receptor for MADCAM1.

CD49d is expressed on most lymphocytes, granulocytes, monocytes, and thymocytes. CD49d/CD29 (VLA-4; α4β1) is expressed at high levels on the surface of lymphohematopoietic progenitors and is involved in their development and proliferation. CD49d/CD29 integrin/VCAM-1 interactions facilitate B cell adhesion to stromal cells and enhance B cell activation. In the absence of alpha-4 integrins, pre-B cells fail to transmigrate and proliferate.

R1-2 was generated by immunizing Fisher rats with TK1, a Peyer’s patch high endothelial venules (HEV) binding lymphoma line². Spleen cells were subsequently fused with nonsecreting mouse myeloma P3x63Ag8.653 cells. Hybridomas producing antibodies reactive with TK1 cells, but not the HEV nonbinding lymphoma TK5, were cloned and screened for inhibition of lymphocyte binding to HEV of either peripheral nodes or Peyer’s patches.

CD49d is expressed on T cells, B cells, NK cells, dendritic cells, thymocytes, monocytes, eosinophils, mast cells.

VCAM-1, MAdCAM-1, fibronectin

1. Holzmann B, Weissman IL. EMBO J. 8(6):1735-1741. 1989.
2. Holzmann B, McIntyre BW, Weissman IL. Cell. 56(1):37-46. 1989.
3. Jin H, Aiyer A, Su J, et al. J Clin Invest. 116(3):652-662. 2006.
4. DeNucci CC, Pagán AJ, Mitchell JS, et al. J Immunol. 184(5):2458-2467. 2010.
5. Uchida Y, Kawai K, Ibusuki A, et al. J Immunol. 186(12):6945-6954. 2011.
6. Hadeiba H, Lahl K, Edalati A, et al. Immunity. 36(3):438-450. 2012.
7. Shokeen M, Zheleznyak A, Wilson JM, et al. J Nucl Med. 53(5):779-786. 2012.
8. Renkema KR, Li G, Wu A, et al. J Immunol. 192(1):151-159. 2014.
9. Hermida MD, Doria PG, Taguchi AM, et al. BMC Infect Dis. 14:450. 2014.
10. Mamedov MR, Scholzen A, Nair RV, et al. Immunity. 48(2):350-363.e7. 2018.
11. Rolot M, Dougall AM, Chetty A, et al. Nat Commun. 9(1):4516. 2018.
12. Martin MD, Sompallae R, Winborn CS, et al. Cell Rep. 31(2):107508. 2020.
13. Müller K, Gibbins MP, Roberts M, et al. EMBO Mol Med. 13(4):e13390. 2021.
14. Barrett SP, Riordon A, Toh BH, et al. J Leukoc Biol. 67(2):169-173. 2000.
15. Lin J, Qin L, Chavin KD, et al. Pathobiology. 63(3):119-132. 1995.
16. Chisholm PL, Williams CA, Lobb RR. Eur J Immunol. 23(3):682-688. 1993.